MAPT and Alzheimer disease: Notably, these modifications negatively regulate tau phosphorylation in a site-specific manner, with decreased O-glycosylation, an apparent essential cause of tau hyperphosphorylation in AD and other tauopathies (perhaps influenced by deficient brain glucose metabolism, a common feature of AD and other tauopathies) (Liu et al., 2004).